Frontline Asciminib Combination in Chronic Phase CML
Frontline Asciminib Combination in Chronic Phase CML
Active, not recruiting · NCT03906292 · Registry updated 2026-08-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Frontline Asciminib Combination in Chronic Phase CML | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-08-18 | NCT03906292 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ludwig-Maximilians - University of Munich | 67 |
| Novartis Pharmaceuticals | 432 |
| University of Jena | 9 |
21 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.